Peter Drucker Society Europe Appoints Sunil Prashara of Project Management Institute to International Advisory Board
1.4.2021 18:00:00 EEST | Business Wire | Press release
Project Management Institute (PMI) and the Peter Drucker Society Europe today announced the launch of a strategic partnership in which PMI President and CEO Sunil Prashara will join the Drucker Society International Advisory Board.
The Peter Drucker Society Europe is a non-profit organization that seeks to advance a critical, international dialogue between management practitioners, academics, and other stakeholders. Their mission is to give a new voice to management in all sectors of society, thus contributing to the continuous improvement of the practice of management. This partnership will complement PMI’s role as the world's leading association for project professionals and changemakers.
“Both organizations are non-profit entities with the shared objective of improving the practice of management in every area of society, from government and public sector to private and not-for-profit bodies,” said Richard Straub, founder and president of the Global Peter Drucker Forum, the annual conference organized by the Drucker Society Europe.
“We are enabling millions of project leaders and changemakers to make important contributions to the world,” Prashara said. “PMI’s mission—to enable individuals to make ideas reality—aligns perfectly with Peter Drucker’s legacy of rigorous thought leadership around management as a systematic discipline entailing research, teaching, and practice. I see the Drucker Forum as a key platform and partner for raising awareness of the fundamental importance of management in building functioning modern societies.”
In support of their mission, the Peter Drucker Society Europe has designated the Global Peter Drucker Forum as a strategic initiative. The forum is an international management conference held annually in Peter Drucker's home city of Vienna, Austria, and is often hailed as the "Davos of Management,” as it has become one of the leading management conferences in Europe. The Global Peter Drucker Forum 2021 is centered on the theme of “The Human Imperative: Navigating Uncertainty in the Digital Age.” Forum stakeholders will take part in a range of discussion on ways to resolve tensions between technocratic and humanistic approaches to crisis, to arrive at a synthesis of "change and continuity."
###
About Project Management Institute
Project Management Institute (PMI) is the world's leading professional association for a growing global community of millions of project professionals and changemakers worldwide.
As the world’s leading authority on project management, PMI empowers people to make ideas a reality. Through global advocacy, networking, collaboration, research, and education. PMI prepares organizations and individuals at every stage of their career journey to work smarter so they can drive success in a world of change.
Building on a proud legacy dating to 1969, PMI is a “for-purpose” organization working in nearly every country around the world to advance careers, strengthen organizational success, and enable changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
Visit us at https://www.pmi.org/, www.projectmanagement.com , https://www.linkedin.com/company/pminstitute , www.facebook.com/PMInstitute , and on Twitter.
About Peter Drucker Society Europe Initiative
The Peter Drucker Society Europe is a practitioner-led, multi-stakeholder group that builds on Peter Drucker’s fundamental ideas and ideals with the aim of contributing to the evolution of management as a vital piece of a functioning modern society. Each year, the Drucker Society Europe hosts the Global Peter Drucker Forum, a crystallizing event where decision makers convene to discuss the future of management in a pragmatic and solution-oriented manner.
To fulfil its mission, the Peter Drucker Society Europe has established legally and financially independent nonprofit Drucker Society chapters in Austria, London, Barcelona and Mannheim. Please note that The Drucker 1996 Literary Works Trust is the owner of the service marks "Peter Drucker", "Peter F. Drucker" and "Drucker".
Learn more at www.druckerforum.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005059/en/
Contact information
PMI Contact:
David Summers | mobile:(610) 930-3425
press@pmi.org
Drucker Forum Contact:
www.druckerforum.org/contact/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 07:00:00 EEST | Press release
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom